Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double‐blind placebo‐controlled trial

Viljanen, Mirva; Savilahti, Erkki; Haahtela, Tari; Juntunen‐Backman, Kaisu; Korpela, Riitta; Poussa, Tuija; Tuure, Tuula; Kuitunen, Mikael

doi:10.1111/j.1398-9995.2004.00514.x

Cited by 434 publications

(358 citation statements)

References 34 publications

Supporting

Mentioning

315

Contrasting

Unclassified

Order By: Relevance

“…Numerous studies support the beneficial effect of living microbial food supplements in health and disease (Marcos et al, 2004;Valeur et al, 2004;De Vrese et al, 2005;Viljanen et al, 2005;Weston et al, 2005;Ewaschuk and Dieleman, 2006;Olivares et al, 2006;Suomalainen et al, 2006). The functional properties of probiotics are strainspecific.…”

Section: Introductionmentioning

confidence: 99%

Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp lactis DGCC 420 modulate unspecific cellular immune response in healthy adults

Friedrich²,

et al. 2007

View full text Add to dashboard Cite

Objective: It was determined whether a combination of Lactobacillus acidophilus (L. acidophilus) 74-2 and Bifidobacterium animalis subsp lactis DGCC 420 (B. lactis 420) affect the faecal microbiota as well as immunological parameters and blood lipids in healthy adults. Design: A placebo-controlled, double-blinded, randomized crossover trial was conducted. Subjects: Twenty-six healthy volunteers (mean age 25 years) were recruited by advertising in academical buildings. All of them completed the study. Methods: After 3-week run-in period, half of the volunteers consumed 300 g/day of yoghurt supplement containing probiotic strains L. acidophilus 74-2 and B. lactis 420, and the other half received the placebo product for a period of 5 weeks. The two groups were crossed during the following 5-week period. Blood and faecal samples were collected at the end of each period. The faecal content of probiotic bacteria, faecal short-chain fatty acids (SCFA), serum lipids and plasma immune system biomarkers were evaluated. Results: Faecal proportions of L. acidophilus and of B. lactis increased significantly from 0.02 to 0.19 and 0.4 to 1.4% (Po0.05), respectively. Percentages of granulocytes and monocytes showing phagocytic activity were significantly elevated from 92 to 95% during probiotic intervention, whereas their oxidative burst activity and specific immune parameters remained unaffected. Fecal SCFA and serum cholesterol levels were not influenced by the probiotics. However, serum concentrations of triacylglyceroles decreased significantly by 11.6% (Po0.05) in the probiotic supplementation period. Conclusions: L. acidophilus and B. lactis were recovered in faeces in significantly elevated numbers after supplementation. They are able to modulate unspecific cellular immune response indicated by the increased phagocytic activity.

show abstract

Section: Introductionmentioning

confidence: 99%

Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp lactis DGCC 420 modulate unspecific cellular immune response in healthy adults

Friedrich²,

et al. 2007

View full text Add to dashboard Cite

show abstract

“…shermanii) did not have a signifi cant effect. 131 Interestingly, the same four probiotics given in combination with a prebiotic reduced the incidence of eczema and atopic eczema and tended to reduce IgEassociated diseases overall in a primary prevention trial. 124 This may suggest that probiotics have different effects in developing compared with in established disease.…”

Section: Probiotics In Allergic Diseasesmentioning

confidence: 99%

“…Others were unable to detect signifi cant differences in the group overall, but found the LGGassociated improvements to be signifi cant in subgroups of children with IgE-associated disease. 131 In the same study, a combination of four probiotics (LGG, L. rhamnosus LC705, B. breve Bb99, and Propionibacterium freudenreichii ssp. shermanii) did not have a signifi cant effect.…”

Section: Probiotics In Allergic Diseasesmentioning

confidence: 99%

Probiotics and immunity

et al. 2009

View full text Add to dashboard Cite

Probiotics are defi ned as live microorganisms that, when administered in adequate amounts, confer a health benefi t on the host, including the gastrointestinal tract. While this benefi cial effect was originally thought to stem from improvements in the intestinal microbial balance, there is now substantial evidence that probiotics can also provide benefi ts by modulating immune functions. In animal models, probiotic supplementation is able to provide protection from spontaneous and chemically induced colitis by downregulating infl ammatory cytokines or inducing regulatory mechanisms in a strain-specifi c manner. In animal models of allergen sensitization and murine models of asthma and allergic rhinitis, orally administered probiotics can straindependently decrease allergen-specifi c IgE production, in part by modulating systemic cytokine production. Certain probiotics have been shown to decrease airway hyperresponsiveness and infl ammation by inducing regulatory mechanisms. Promising results have been obtained with probiotics in the treatment of human infl ammatory diseases of the intestine and in the prevention and treatment of atopic eczema in neonates and infants. However, the fi ndings are too variable to allow fi rm conclusions as to the effectiveness of specifi c probiotics in these conditions.

show abstract

“…The age range of subjects included varies between studies: around weaning (median 5 months old) (Brouwer et al, 2006;Isolauri et al, 2000;Kirjavainen et al, 2003;Viljanen et al, 2005b;Gruber et al, 2007), around 1 year old (Weston et al, 2005;Folster-Holst et al, 2006), and around 5 years old (Rosenfeldt et al, 2003(Rosenfeldt et al, , 2004Sistek et al, 2006;Woo et al, 2010). Seven of these publications describe effects of Lactobacillus rhamnosus GG LGG in infants but report contradictory results (Brouwer et al, 2006;Isolauri et al, 2000;Kirjavainen et al, 2003;Viljanen et al, 2005b;Gruber et al, 2007;Folster-Holst et al, 2006;Nermes et al, 2011). Two of them (Isolauri et al, 2000;Kirjavainen et al, 2003) showed a significant decrease of the SCORAD score, but both these studies included only small groups of infants (27 and 35).…”

Section: Clinical Impact Of Probiotics In Atopic/allergic Diseases 4mentioning

confidence: 99%

Microbiota and Allergy: From Dysbiosis to Probiotics

Waligora‐Dupriet¹,

Butel²

2012

Allergic Diseases - Highlights in the Clinic, Mechanisms and Treatment

View full text Add to dashboard Cite

Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double‐blind placebo‐controlled trial

Abstract: Treatment with LGG may alleviate AEDS symptoms in IgE-sensitized infants but not in non-IgE-sensitized infants.

Cited by 434 publications

References 34 publications

Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp lactis DGCC 420 modulate unspecific cellular immune response in healthy adults

Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp lactis DGCC 420 modulate unspecific cellular immune response in healthy adults

Probiotics and immunity

Microbiota and Allergy: From Dysbiosis to Probiotics

Contact Info

Product

Resources

About